Terumo India, the Indian arm of the Japan-based Medtech company, recently announced the launch of Occlusafe and LifePearl, for use in liver cancer control in the country.
Hepatocellular carcinoma (HCC) is the number one most common type of liver cancer, with more than 20,000 additional cases a year in India. According to experts, HCC can be treated with control approaches ranging from surgical resection to minimally invasive options.
“Embolization is one of those minimally invasive control options. This blocks the blood supply to the tumor. This deprives the tumor of nutrients and oxygen, which induces the death of those tumor cells. The most common type of embolization is transcatheter arterial chemoembolization (TACE), a minimally invasive clinical management option for intermediate-stage liver cancer,” the company said in a statement.
For the first time in India, Terumo has brought a complex treatment called Balloon-TACE (B-TACE) for the control of liver cancer. With Terumo’s B-TACE device, Occlusafe, patients benefit from more accurate and targeted delivery of chemotherapy treatment. drug to the tumor. In addition, damage to surrounding healthy tissue is minimized, the company claims.
This is related to accelerated reaction rates, with far fewer repeat treatments needed for TACE alone. This provides an opportunity to maintain liver function, he adds.
LifePearl is another added value to introduce in the field of liver cancer care. According to the company, LifePearl is helping deliver chemotherapy drugs in a controlled and sustained manner to the target tumor within the liver.
Occlusafe and LifePearl are known for their clinical outcomes in liver cancer patients treated with TACE.
“At Terumo, our project is to contribute to society through healthcare. Our goal is to bring the newest Japanese medical technologies to India to improve the quality of care for patients and doctors. Occlusafe™ and Lifepearl will offer choice control features to help the liver. cancer care in India,” said Shishir Agarwal, MD, Terumo India.
Terumo India aims to expand its interventional oncology portfolio with new curative responses and provide a more comprehensive toolkit for cancer care management. His commitment to advancing healthcare in India is based on cutting-edge studies and generation through a deep understanding of the healthcare system.
Terumo India is part of Terumo Corporation, a global leader in medical generation headquartered in Tokyo, Japan. With 100 years of experience, Terumo’s broad portfolio of medical devices ranges from vascular intervention, cardiosurgical solutions, blood transfusion and mobile treatment generation to medical products. essential for clinical practice.